71
71
73
73
78
78
88
88
84
84
75
75
81
81
78
78
68
68
61
61
2012
2002
Research Institution (2.4K)University (465)Company (67)Hospital (60)Foundation (6)
1 - 10 of 2,455
Sort by
Clinical Trial
Clinical Trial IDNCT04154111Start Date2020-06-01Completion Date2024-08-01PhaseN/AStudy TypeInterventionalStatusNot yet recruiting
There is growing interest in the utilization of transcranial magnetic stimulation (TMS) as a novel, non-pharmacologic approach to decreasing alcohol use among treatment-seeking individuals with Alcohol Use Disorder (AUD). The results of this study will be used to determine which of the 2 proposed TMS strategies has a larger effect on drinking behavior (% days abstinent, % heavy drinking days) as well as alcohol cue-reactivity in a 4 month period. These data will pave the way for TMS to be use…
Clinical Trial
Clinical Trial IDNCT04052139Start Date2020-06-01Completion Date2022-01-01PhasePhase 2Study TypeInterventionalStatusNot yet recruiting
This study is a 3-arm pilot, randomized, double-blinded, placebo-controlled study of low-dose naltrexone and gabapentin versus placebo among HIV-positive persons with heavy alcohol use and chronic pain to provide estimates of their effects on 1) pain; 2) inflammation; and 3) measures of HIV control. Participants will be followed for 12 weeks. Assessments of study outcomes will be compared at week 8 (end of treatment phase).
Clinical Trial
Clinical Trial IDNCT04090723Start Date2020-06-01Completion Date2021-03-01PhaseN/AStudy TypeInterventionalStatusNot yet recruiting
Unhealthy alcohol use among women with and at risk for HIV can interrupt critical steps in the HIV prevention and care continuum, is associated with HIV transmission risk behaviors, and contributes to health disparities. Thus it is critical to accurately identify alcohol use and implement alcohol interventions among women with and at risk for HIV to optimize health outcomes. The proposed pilot randomized clinical trial will examine the implementation and effects of a computer delivered brief …
Clinical Trial
Clinical Trial IDNCT04243759Start Date2020-06-01Completion Date2021-04-01PhaseN/AStudy TypeInterventionalStatusNot yet recruiting
The proposed study will address a critical knowledge gap: there are no evidence-based smartphone apps for reducing young adult drinking. The purpose of the study is to test alcohol-related smartphone applications designed to provide assistance during actual drinking situations to help young adults reduce their drinking. It is the researchers hypothesis that participants will self-administer less alcohol when using the experimental app with feedback.
Publication
ID32407464Published Date2020-05-14JournalChemical senses, 2020-05-14
A wealth of rapidly evolving reports suggests that olfaction and taste disturbances may be manifestations of the novel COVID-19 pandemic. While otolaryngological societies worldwide have started to consider chemosensory evaluation as a screening tool for COVID-19 infection, the true nature of the relationship between the changes in chemosensory ability and COVID-19 is unclear. Our goal with this review is to provide a brief overview of published and archived literature, as well as the anecdot…
Clinical Trial
Clinical Trial IDNCT04244032Start Date2020-05-01Completion Date2024-08-01PhaseN/AStudy TypeInterventionalStatusNot yet recruiting
Alcohol use disorder is characterized by widespread neurocognitive impairments, however despite substantial advances in the intervention and treatment of alcohol use disorders, exceptionally few studies have been directed to improving these deficits. This project leverages computerized cognitive training, applied as an adjunct to inpatient treatment, to enhance neurocognitive recovery. This project informs public health and future intervention efforts by interrogating factors critical to inte…
Clinical Trial
Clinical Trial IDNCT04331704Start Date2020-05-01Completion Date0031-07-30PhasePhase 4Study TypeInterventionalStatusNot yet recruiting
80 young adult men will complete an initial survey and receive 1 of 2 types of alcohol and sexual health education and information to encourage prevention of alcohol-related problems, HIV and other sexually transmitted infections (STIs). Participants will then take pre-exposure prophylaxis (PrEP) for HIV prevention and complete a daily 5-minute, telephone-based interactive voice response (IVR) assessment of alcohol/substance use, sexual behavior and PrEP taking for 30 days. Medication will al…
Publication
ID32349118Published Date2020-04-29JournalNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020-04-29
Lithium remains the gold standard for the treatment of bipolar disorder (BD); however, its use has declined over the years mainly due to the side effects and the subjective experience of cognitive numbness reported by patients. In the present study, we aim to methodically test the effects of lithium on neurocognitive functioning in the largest single cohort (n = 262) of BD patients reported to date by harnessing the power of a multi-site, ongoing clinical trial of lithium monotherapy. At the …
Clinical Trial
Clinical Trial IDNCT04247191Start Date2020-07-01Completion Date2023-11-01PhaseN/AStudy TypeInterventionalStatusNot yet recruiting
College students' alcohol use continues to be a major public health problem. Among the many consequences of this risky behavior are impaired driving and impaired passenger fatalities. Both college health administrators and parents have requested parent-based interventions (PBIs), and parents have demonstrated ample motivation to communicate with their teens. The proposed research will attempt to enhance an existing effective PBI, curb the alarming trends noted in the literature, and move the …
Publication
ID31926199Published Date2020-04-01JournalPharmacology & therapeutics, 2020-04-01, Volume 208
Endocannabinoids acting via CB receptors (CBR) play a critical role in regulating energy homeostasis, which was the rationale for the pharmaceutical development of CBR antagonists for the treatment of obesity. Although the first-in-class CBR antagonist rimonabant proved to be effective in mitigating obesity and its multiple cardiometabolic complications, it was withdrawn from clinical use due to CNS-mediated neuropsychiatric side effects, which halted the further therapeutic development of th…
We found 2,455 documents that match your Search
Research Grants: 1,793
Publications: 85
Clinical Trials: 577

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in